ASLAN Says 'The eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance'
Portfolio Pulse from Benzinga Newsdesk
ASLAN Pharmaceuticals announced that the eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints with statistical significance.
July 06, 2023 | 11:59 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ASLAN Pharmaceuticals' eblasakimab 400mg Q4W dosing arm did not meet the primary or secondary endpoints, which could negatively impact the company's stock price.
The failure of a pharmaceutical company's drug to meet primary or secondary endpoints in clinical trials often leads to a decrease in the company's stock price. This is due to the potential loss of revenue from the drug and the costs associated with the failed trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100